论文信息 - RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study - 字舞流文

RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study

C. Tournigand | C. Borg | T. Mazard | D. Vernerey | Y. Menu | M. Svrcek | T. André | D. Tougeron | R. Cohen | J. Bennouna | C. de la Fouchardière | B. Chibaudel | A. Meurisse | Marie-Line Garcia-Larnicol | C. de la Fouchardiére